Details About Generic Salt ::  Beractan

Main Medicine Class:: Lung surfactant   

(ber-ACT-ant)

Survanta

Class: Lung surfactant

 

Drugs Class ::

 Action Replaces deficient endogenous pulmonary surfactant and restores surface activity of lung.

Indications for Drugs ::

 Indications Prevention and treatment (“rescue”) of neonatal respiratory distress syndrome (RDS) in premature infants.

Drug Dose ::

 Route/Dosage

NEONATES & INFANTS: Intratracheal PREVENTION: 25 mg/kg/instillation for 4 instillations (total dose of 100 mg/kg is administered in 4 quarter doses); dose is started within 15 min. of birth. RESCUE: 25 mg/kg/instillation for 4 instillations (total dose 100 mg/kg). May be repeated for continued or progressive RDS.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Administer drug only by trained personnel in a closely-supervised setting. Nosocomial sepsis: Occurred in controlled clinical trials.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CNS: Intracranial hemorrhage.

Drug Mode of Action ::  

 Action Replaces deficient endogenous pulmonary surfactant and restores surface activity of lung.

Drug Interactions ::

 Interactions None well documented.

Drug Assesment ::

 Assessment/Interventions

• If possible, review mother’s patient history.
• Take baseline vital signs and monitor during and after medication administration.
• Avoid suctioning patient for 1 hr after administration unless airway is obstructed.
• Have emergency equipment available for cardiac or respiratory complications.
• Monitor lung sounds for any changes (eg, rales or moist sounds).
• Observe for signs of nosocomial infection/sepsis.
• Continually monitor oxygen and carbon dioxide measurements. If oxygen saturation decreases or bradycardia develops, discontinue administration until patient is stabilized.

OVERDOSAGE: SIGNS & SYMPTOMS   Acute airway obstruction (based on animal studies)

Drug Storage/Management ::

 Administration/Storage

• Warm medication by allowing it to stand at room temperature for 20 min or in hand for 8 min. Do not use artificial warming methods.
• If settling has occurred, swirl gently; do not shake.
• If preventive dose is planned, begin preparation before infant’s birth.
• Before administering, assure proper placement and patency of endotracheal (ET) tube. If suctioning is required, allow patient to stabilize before administering.
• Instill through small (5 Fr) catheter inserted into ET tube with tip above carina. Do not instill into main stem bronchus. Attach catheter to syringe. Fill with medication and discard any excess through catheter to ensure that total dose to be given remains in syringe. After each quarter dose remove catheter and mechanically ventilate patient for 30 sec. Continue procedure until total dose is achieved. Administer each quarter dose with infant in different position.
• Store unopened vials under refrigeration and protect from light.
• Warmed unopened vials (< 8 hr) can be returned to refrigerator for future use. Drug should not be warmed and refrigerated more than once. Discard any open vials.

Drug Notes ::

 Patient/Family Education

• Advise family of infant’s condition and offer frequent updates.
• Encourage active family participation in care whenever possible.
• Provide emotional support; offer hospital services and support groups.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.